San Diego Stock Exchange

SEARCH SAN DIEGO STOCKS:

Symbol

GEN-PROBE INC

Symbol	Name	Close	Change		Volume	Dayhigh	Daylow
GPRO	Gen-Probe	46.48	0.45	+ 0.98%	217652.00	46.92	46.36

Exchange	Earningspershare	52-Week High	52-Week Low
NASDAQ N-Mkt	1.82	51.33	38.35

SourceBook Information

Gen-Probe Inc. is listed in:

• Biomed & Biotech Firms -
• Biomed & Biotech Firms - Publicly Traded -
• Highest Paid CEOs of BIO Tech Companies -
• Largest Public Employers -
• Local Publicly Traded Companies -

Contact Information

Company Name

Gen-Probe Inc.

Executives

Henry L. Nordhoff, Chairman/President/CEO

Address

10210 Genetic Center Drive

San Diego, CA 92121

Phone

(858) 410-8000

Fax

(858) 410-8625

E-mail

ir@gen-probe.com

Web Page

www.gen-probe.com

Business Information

Parent Company

n/a

Business Description

Development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid prob-based products used for the clinical diagnosis of human diseases and for screening donated human blood.

SIC Code

8731

Headquarters

San Diego, CA

Local Mailing Address

10210 Genetic Center Drive, San Diego, CA 92121

Year Established

1983

Year Established in San Diego

1983

Publicly Traded?

Yes

Ticker Symbol

GPRO

Market Capitalization

$2,221,534,000

Total Number of Employees

809

Number of Local Employees

809

Number of Offices Local

n/a

Gross Revenue 2003 Year End

wnd

Gross Revenue 2002 Year End

wnd

Number of Employees Companywide

843

Business Services

n/a

Industries of Interest

Scientific & Technical Instr.

Gross Revenue 2000

$119,541,000

Gross Revenue 2000 Year End

wnd

Gross Revenue 2001

$129,731,000

Gross Revenue 2001 Year End

wnd

Gross Revenue 2002

$155,597,000

Gross Revenue 2003

$207,191,000

Gross Revenue 2004

wnd

Gross Revenue 2005 YTD, Local

wnd

Gross Revenue 2007

n/a

Gross Revenue 2009

n/a

Gross Revenue 2010

n/a

Manufacturer

Yes

Mission Statement

n/a

Fields of Research

Nucleic acid diagnostics for human disease

Major Products

Develop, manufacture, and market rapid, accurate nucleic acid tests (NAT) to diagnose human diseases and screen donated blood.

Major Investors

Institutional Investors

Number of Products Approved For Sale

60+

Patents

n/a

Number of Products In Development

20+

Strategic Alliances

AdnaGen, Bayer, BioMerieux, Chiron, Corixa, DiagnoCure, Qualigen, RebioGen, Tosoh

Services Offered

n/a

Chief Executive Officer

Henry L. Nordhoff

Date CEO Began

Jul. 1994

Total Annual CEO Compensation (salary & bonuses)

$930,000 (FY 2004)

CEO Salary

$530,000 (FY 2004)

CEO Bonuses

$400,000 (FY 2004)

Gross Revenue 2006

n/a

Sales for 2006

n/a

Gross Revenue 2008

n/a